The Warp Speed Push for Coronavirus Vaccines
By F. William Engdahl
18 May 2020
Image Credit: Maryland GovPics: Emma Walmsley and Moncef Slaoui, December
2016. License: Creative Commons Attribution 2.0 Generic with conditions https://cutt.ly/NyTn9OD
The US White House has appointed a coronavirus “Vaccine Czar” from Big
Pharma to oversee something dubbed Operation Warp Speed. The goal is to create
and produce 300 million doses of a new vaccine to supposedly immunize the
entire US population by year-end against COVID-19. To be sure that Big Pharma
companies give their all to the medical Manhattan Project, they have been fully
indemnified by the US government against liabilities should vaccine recipients
die or develop serious disease as a result of the rushed vaccine. The FDA and
NIH have waived standard pre-testing on animals in the situation. The US
military, according to recent remarks by the US President, is being trained to
administer the yet-to-be unveiled vaccine in record time. Surely nothing could
go wrong here ?
Warp speed is a term out of the sci-fi Star Trek media, defined as a
speed faster than the speed of light. In recent weeks billions of dollars have
been pledged from governments, from the Bill and Melinda Gates Foundation and
others to fast-track a vaccine as well as test medical treatments to combat the
VODIV19 illness said to originate from a novel coronavirus first discovered
late 2019 in Wuhan China. This rush to create a “miracle” vaccine is ominous
and suggests some hidden agenda.
The Conflicted Czar
Washington’s Operation Warp Speed is reportedly the brainchild of
Presidential Adviser and son-in-law Jared Kushner. It is being formally run by
the Health and Human Services Secretary Alex Azar and Defense Secretary Mark
Esper who will work with a new Vaccine Czar. The Vaccine Czar selected for
Kushner’s Operation Warp Speed is former GlaxoSmithKline Chairman of its
Vaccines Division, Morrocan-born US citizen, Dr. Moncef Slaoui. From 2006
through 2017 Slaoui was Chairman of Global R&D and Vaccines at
GlaxoSmithKline and sat on the company’s Executive team and Board of Directors.
While at GSK Slaoui headed the development of Cervarix. Its Cervarix HPV
cervical cancer vaccine was reported tied to multiple deaths or severe
crippling effects in many recipients. A 2017 WHO monitoring report revealed
that serious adverse effects from Moncef Slaoui’s HPV vaccine included complex
regional pain syndrome (CRPS), postural orthostatic tachycardia syndrome (POTS)
and chronic fatigue syndrome (CFS) that “exceeds any
other vaccine.” That is not reassuring in terms of the new Czar
of a rushed coronavirus vaccine.
In 2015 the Indian Supreme Court investigated charges that young Indian
village girls died after being given Cervarix from Slaoui’s GSK. It was done in
illegal vaccine “human guinea pig” tests of the HPV vaccine where neither the
girls nor their parents were told what it was. The study was reportedly funded by the Bill and Melinda
Gates Foundation.
In 2012 while Slaoui headed GSK global R&D and vaccine development,
and sat on the GSK board, the company was fined $3 billion by the US Department
of Justice, the largest ever fine against a pharmaceutical company. Among the
charges was that GlaxoSmithKline deliberately withheld alarming safety data for
its major-selling diabetes drug, Advandia, from the US FDA. After Advandia
quietly vanished from the product list of GSK.
Slaoui also has ties to the projects of the Bill & Melinda Gates
Foundation. He sat on the board of the Gates-funded International AIDS Vaccine
Initiative. The IAVI was initiated in 1994 at a Rockefeller Foundation
conference and is backed among others by the Gates
Foundation, by the US Department of Defense and by Tony Fauci’s National
Institute of Allergy and Infectious Diseases.
At a May 15 White House press conference where the President introduced
Slaoui as the head of the crash vaccine project, Slaoui stated, “Mr. President,
I have very recently seen early data from a clinical trial with a coronavirus
vaccine. These data make me feel even more confident that we will be able to
deliver a few hundred million doses of vaccine by the end of 2020.”
Though he did not say, he was clearly referring to Moderna and its mRNA
gene-edited vaccine, the first US vaccine authorized to enter Phase I human
trials after the US government gave the company a staggering $483 million of
funding to fast-track the COVID-19 vaccine.
Vaccine Czar Slaoui is well-placed with regard to Moderna. After leaving
GSK from 2017 until he joined the Trump Operation Warp Speed, Slaoui was on the
Moderna Board of Directors. He also still holds $10 million
worth of Moderna stock
options, options likely to soar in value as the Warp
Speed zooms forward. This would suggest a glaring conflict of interest with
Czar Slaoui, but that’s only the start of this saga, where millions of lives
are potentially at threat from a novel inadequately-tested or proven
genetically edited vaccine.
Moderna and Slaoui
At this point the leading US Government candidate for winning the “warp
speed” race to roll out a COVID-19 vaccine is Slaoui’s Moderna Inc. in
Cambridge, Massachusetts. That’s surely a coincidence?
Moderna claims that between January 11, when they got the DNA sequence
of the virus from China, and January 13–in just two days–working together with
Anthony Fauci’s National Institute of Allergies and Infectious Diseases (NIAID)
of NIH, they managed to finalize the sequence for mRNA1273 vaccine against the
novel coronavirus. At that point Fauci announced unprecedented plans to run
human Phase I trials of the vaccine without prior animal studies. The FDA
waived animal pretest requirements. The Moderna mRNA1273 tests were funded by the Gates
Foundation-funded Coalition for Epidemic Preparedness Innovations (CEPI).
The focus by Fauci on Moderna’s mRNA experimental COVID-19 vaccine while
Slaoui was heading its development at Moderna is impressive to say the least.
The company states that on April 16, Moderna got an award from US government
agency BARDA for $483 million to accelerate development of mRNA-1273. This
award will fund the development of mRNA-1273 to FDA licensure and manufacturing
process scale-up to enable large-scale production in 2020 for pandemic
response. At that point the stock value of Slaoui’s Moderna stock options
jumped 184%. Then, on May 1, Moderna and Lonza Group announced a worldwide
strategic collaboration to manufacture mRNA-1273 at a planned 1 billion
doses per year. This is no small deal.
On May 6, Moderna filed a Current Report on Form 8-K with the SEC, which
included an interview published by National Geographic with Anthony S. Fauci,
Director of NIAID, which described his assessment of the results of testing
related to the ongoing Phase 1 clinical
study of mRNA-1273. It was quite positive.
So, between January 13 and March 25, Slaoui and his team at Moderna were
able to design the vaccine, and to produce it in such a way that it can be
injected in humans, Slaoui told a Moroccan magazine, L’Economiste. While with
Moderna, Slaoui was fully involved in the development of the mRNA COVID-19
vaccine.
On May 7 just days before Slaoui became the Trump Vaccine Czar, the US
Food and Drug Administration (FDA) approved the gene-edited messenger RNA
(mRNA) vaccine, mRNA1273, to go into a Phase II human trial in the summer. On
May 12, the FDA gave Fast Track Designation for Moderna’s mRNA Vaccine. Warp Speed,
you know.
The FDA with the backing of Tony Fauci’s NIAID in the NIH, granted
unprecedented Phase I human trials of the never-before approved mRNA vaccine on
April 27. They skipped normal animal, usually rat, testing, to go directly to
human guinea pig tests. Moderna says Phase II trial will assess the safety,
reactogenicity, and immunogenicity of two vaccinations of mRNA-1273 given 28
days apart. They will enroll 600 healthy adults for the experiment and
supposedly follow their health for 12 months after the second
vaccination. second vaccination. The plan is to begin human
vaccinations by year end.
Dangers of mRNA?
All this, despite the evidence of extreme conflicts of interest between
NIAID and other agencies of the US Government with Moderna and now-Vaccine Czar
and former Moderna director Slaoui, might be treated more lightly, were it not
for the fact that Moderna’s mRNA gene-edited vaccine technology is entirely
experimental and never before approved for use as a vaccine. The company itself
admits as much. It says, “mRNA is an emerging platform… we are still early in
the story. Our most advanced vaccine program (CMV) is in Phase 2 clinical
testing and we have no approved
drugs to date.”
Moderna and others working with the experimental gene-edited mRNA
vaccines claim they are safer than the admittedly unpredictable gene-edited DNA
vaccines. DNA vaccine research is thirty years old but to date, has failed to
produce a single licensed DNA vaccine. Moderna is only 11 years old and the
CRISPR gene-editing technology it uses is barely 5 years old. We are told mRNA
is completely different and safe.
However, numerous scientists warn that once inside the cell nucleus,
mRNA vaccines have a risk of permanently changing a person’s DNA in
unpredictable ways. Tony Faudi’s own NIH published a scientific paper regarding
the new mRNA vaccine prospects. It read in part, “innate immune sensing of mRNA
has also been associated with the inhibition of antigen expression and may
negatively affect the immune response. Although the paradoxical effects of
innate immune sensing on different formats of mRNA vaccines are incompletely
understood, some progress has been made in recent years in elucidating these
phenomena.” This is highly experimental
science.
Another scientific paper funded by several Chinese universities and
republished by the NIH in 2019, reviewing the development of the new messenger
RNA technique for vaccines sounded some sober warnings. It noted that there
were “Concerns with instability and low immunogenicity.” Further that, “mRNA
vaccines are efficient at antigen expression, but sequence and secondary
structures formed by mRNAs are recognized by a number of innate immune
receptors, and this recognition can inhibit protein translation.” Not only
that, but “…several of these delivery vehicles demonstrated toxicity in vivo,
which may limit their use in humans.”(emphasis added). The authors concluded
that “The immune response mechanism instigated by mRNA remains to be
elucidated. The process of mRNA vaccine recognition by cellular sensors and the
mechanism of sensor activation are still not clear.”
The US government, in a
tight-knit circle all tied to Tony Fauci’s NIAID, the Gates Foundation, WHO are
moving with not warp, but rather warped human priorities to deliver us a
vaccine that no one can assure is in any way safe. Were Moderna so certain it
is safe, they should offer to be legally liable for any mRNA damage. They
don’t, nor do any vaccine companies. We need to decide if the scale of the
worldwide deaths, inflated or not, alleged to be of COVID-19, warrant such a
human experiment that could alter our genetics in unpredictable and possibly
toxic ways.
F. William Engdahl is strategic risk consultant and lecturer, he holds a
degree in politics from Princeton University and is a best-selling author on
oil and geopolitics, exclusively for the online magazine “New Eastern
Outlook”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.